Related Experiment Video
Updated: May 21, 2026
14:34
A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
Published on: April 3, 2026
Lead optimization of antimalarial propafenone analogues
David Lowes1, Anupam Pradhan, Lalitha V Iyer
1Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Journal of Medicinal Chemistry
|June 20, 2012
Summary
New antimalarial drug candidates show promise. These propafenone analogues are orally bioavailable, nontoxic in rodent models, and effectively suppress malaria parasites, paving the way for further development.
Area of Science:
- Medicinal Chemistry
- Parasitology
- Pharmacology
Background:
- Analogues of propafenone have demonstrated potent antimalarial activity.
- These compounds exhibited reduced cardiac ion channel activity, suggesting potential for clinical development.
- Previous research indicated promising properties for malaria treatment.
Purpose of the Study:
- To evaluate the bioavailability, pharmacokinetics, toxicology, and efficacy of propafenone analogues.
- To assess the in vivo antimalarial potential of these compounds in rodent models.
- To identify challenges and opportunities for further preclinical development.
Main Methods:
- Rodent models were utilized to examine key pharmacokinetic and toxicological parameters.
- In vivo efficacy was assessed by measuring the suppression of parasitemia.
- A comprehensive analysis of bioavailability and drug metabolism was conducted.
Main Results:
- Orally bioavailable compounds were identified within the propafenone analogue series.
- The identified compounds demonstrated a lack of toxicity in the tested rodent models.
- Significant suppression of parasitemia in vivo was observed, confirming antimalarial activity.
Conclusions:
- Propafenone analogues represent a promising class of compounds for antimalarial drug development.
- The identified compounds are orally bioavailable, nontoxic, and effective in vivo.
- Further preclinical development is warranted, though significant challenges remain.
Related Concept Videos
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
01:30Prodrugs
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...